1 Min Read
Feb 23 (Reuters) - Madrigal Pharmaceuticals Inc
* Madrigal Pharmaceuticals announces the initiation of a Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.